CGEM – cullinan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
Form 4 Cullinan Therapeutics, For: Feb 25 Filed by: SUMER JACQUELYN L
Form 4 Cullinan Therapeutics, For: Feb 25 Filed by: Michaelson Jennifer
Form 4 Cullinan Therapeutics, For: Feb 25 Filed by: AHMED NADIM
Form 4 Cullinan Therapeutics, For: Feb 25 Filed by: Jones Jeffrey Alan
Form S-8 Cullinan Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.